Orphan Medicinal Products

Orphan medicinal products are intended for the analysis, prevention or treatment of dangerous or very serious conditions that affect no more than 5 in 10,000 people in the European Union. Patients suffering from rare diseases deserve the same quality of treatment as other patients within the European Union. Given the small numbers of patients affected by rare diseases, the pharmaceutical industry has been unwilling in the past to invest in the research and development of medicinal products to treat them. The EU introduced new legislation in 2000 with the aim of providing incentives for the development of medicines for rare diseases (so-called orphan medicinal products).

    Related Conference of Orphan Medicinal Products

    March 13-14, 2025

    9th International Conference on Rare Diseases

    Prague, Czech Republic
    March 17-18, 2025

    12th International Congress on Infectious Diseases

    Berlin, Germany
    April 14-15, 2025

    15th European Epidemiology and Public Health Congress

    Budapest, Hungary
    June 02-03, 2025

    14th World Congress on Rare Diseases and Orphan Drugs

    Amsterdam, Netherlands
    June 02-03, 2025

    17th Euro-Global Conference on Infectious Diseases

    Amsterdam, Netherlands

    Orphan Medicinal Products Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in